Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;46(2):90-110.
doi: 10.1007/s12272-023-01431-8. Epub 2023 Feb 2.

Tumor lactic acid: a potential target for cancer therapy

Affiliations
Review

Tumor lactic acid: a potential target for cancer therapy

Jun-Kyu Byun. Arch Pharm Res. 2023 Feb.

Abstract

Tumor development is influenced by circulating metabolites and most tumors are exposed to substantially elevated levels of lactic acid and low levels of nutrients, such as glucose and glutamine. Tumor-derived lactic acid, the major circulating carbon metabolite, regulates energy metabolism and cancer cell signaling pathways, while also acting as an energy source and signaling molecule. Recent studies have yielded new insights into the pro-tumorigenic action of lactic acid and its metabolism. These insights suggest an anti-tumor therapeutic strategy targeting the oncometabolite lactic acid, with the aim of improving the efficacy and clinical safety of tumor metabolism inhibitors. This review describes the current understanding of the multifunctional roles of tumor lactic acid, as well as therapeutic approaches targeting lactic acid metabolism, including lactate dehydrogenase and monocarboxylate transporters, for anti-cancer therapy.

Keywords: Anti-tumor therapy; Lactate dehydrogenases; Lactic acid; Lactic acid blocking strategy; Monocarboxylate transporters; Tumors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Afonso J, Santos LL, Morais A, Amaro T, Longatto-Filho A, Baltazar F (2016) Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness. Cell Cycle 15:368–380. https://doi.org/10.1080/15384101.2015.1121329 - DOI
    1. Ahmed K, Tunaru S, Tang C, Muller M, Gille A, Sassmann A, Hanson J, Offermanns S (2010) An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metab 11:311–319. https://doi.org/10.1016/j.cmet.2010.02.012 - DOI
    1. Angelin A, Gil-De-Gomez L, Dahiya S, Jiao J, Guo L, Levine MH, Wang Z, Quinn WJ 3rd, Kopinski PK, Wang L, Akimova T, Liu Y, Bhatti TR, Han R, Laskin BL, Baur JA, Blair IA, Wallace DC, Hancock WW, Beier UH (2017) Foxp3 reprograms T cell metabolism to function in low-glucose high-lactate environments. Cell Metab 25:1282-1293 e1287. https://doi.org/10.1016/j.cmet.2016.12.018 - DOI
    1. Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernandez-Perez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM, Medico E, Pietrantonio F, Volante M, Pasini D, Chiarugi P, Giordano S, Corso S (2018) Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. Cell Metab 28:848-865 e846. https://doi.org/10.1016/j.cmet.2018.08.006 - DOI
    1. Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, Murphy SC, Erlichman C, Rudin CM, Govindan R, Mayo Phase C, California C (2011) A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 6:1757–1760. https://doi.org/10.1097/JTO.0b013e31822e2941 - DOI

LinkOut - more resources